Castle Biosciences CCO reports insider sales under 10b5-1

Q: What insider transaction did CSTL disclose on Form 4?

The Chief Commercial Officer reported selling 500 shares on 11/11/2025 at a weighted-average price of $35.39 , and 200 shares on 11/12/2025 at $35.40 .

Q: Was the CSTL insider sale under a 10b5-1 plan?

Yes. The sales were made under a Rule 10b5-1 plan adopted on September 11, 2024 .

Q: How many CSTL shares does the officer own after the transactions?

The officer reported 84,027 shares held directly and 2,230 shares held indirectly through a family revocable trust.

Q: What were the sale prices for the CSTL shares?

The 11/11/2025 sale reflects a weighted-average price of $35.39 (range: $35.38–$35.40). The 11/12/2025 sale was at $35.40 .

Q: What is the reporting person’s role at CSTL?

The reporting person is CSTL’s Chief Commercial Officer .

Q: How are the indirect CSTL shares held?

They are held by the Tobin W and Susan M Juvenal Family Revocable Trust , with the officer and spouse as trustees.

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Castle Biosciences (CSTL) reported an insider transaction by its Chief Commercial Officer on Form 4. The officer sold 500 shares of common stock on 11/11/2025 at a weighted-average price of $35.39 pursuant to a Rule 10b5-1 plan adopted on September 11, 2024. A separate sale of 200 shares occurred on 11/12/2025 at $35.40.

Following these transactions, the officer reported 84,027 shares held directly. In addition, 2,230 shares are held indirectly by the Tobin W and Susan M Juvenal Family Revocable Trust, of which the officer and spouse are trustees and beneficiaries include the officer, spouse, and their children.

Insider Trade Summary

Net Seller: 700 shares ($24,775)

Net Sell 3 txns

Insider Juvenal Tobin W

Role Chief Commercial Officer

Sold 700 shs ($25K)

Type	Security	Shares	Price	Value
Sale	Common Stock	200	$35.40	$7K
Sale	Common Stock	500	$35.39	$18K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 83,827 shares (Direct); Common Stock — 2,230 shares (Indirect, By Tobin W and Susan M Juvenal Family Revocable Trust)

Footnotes (1)

This transaction was made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 11, 2024. This transaction was executed in multiple trades at prices ranging from $35.38 to $35.40, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed at a price of $35.40. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Held by Tobin W and Susan M Juvenal Family Revocable Trust of which the Reporting Person and his spouse are the trustees and the Reporting Person, his spouse and their children are the beneficiaries.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

11/13/2025 - 04:08 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Juvenal Tobin W

(Last)

(First)

(Middle)

C/O CASTLE BIOSCIENCES, INC.

505 S FRIENDSWOOD DRIVE, SUITE 401

(Street)

FRIENDSWOOD

77546

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
CASTLE BIOSCIENCES INC [ CSTL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/11/2025		S⁽¹⁾		500	D	$35.39⁽²⁾	84,027	D
Common Stock	11/12/2025		S⁽¹⁾		200	D	$35.4⁽³⁾	83,827	D
Common Stock								2,230	I	By Tobin W and Susan M Juvenal Family Revocable Trust⁽⁴⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction was made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 11, 2024.

2. This transaction was executed in multiple trades at prices ranging from $35.38 to $35.40, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

3. This transaction was executed at a price of $35.40. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

4. Held by Tobin W and Susan M Juvenal Family Revocable Trust of which the Reporting Person and his spouse are the trustees and the Reporting Person, his spouse and their children are the beneficiaries.

Remarks:

	/s/ Frank Stokes, Attorney-in-fact	11/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did CSTL disclose on Form 4?

The Chief Commercial Officer reported selling 500 shares on 11/11/2025 at a weighted-average price of $35.39, and 200 shares on 11/12/2025 at $35.40.

Was the CSTL insider sale under a 10b5-1 plan?

Yes. The sales were made under a Rule 10b5-1 plan adopted on September 11, 2024.

How many CSTL shares does the officer own after the transactions?

The officer reported 84,027 shares held directly and 2,230 shares held indirectly through a family revocable trust.

What were the sale prices for the CSTL shares?

The 11/11/2025 sale reflects a weighted-average price of $35.39 (range: $35.38–$35.40). The 11/12/2025 sale was at $35.40.

What is the reporting person’s role at CSTL?

The reporting person is CSTL’s Chief Commercial Officer.

How are the indirect CSTL shares held?

They are held by the Tobin W and Susan M Juvenal Family Revocable Trust, with the officer and spouse as trustees.